BioCentury
ARTICLE | Clinical News

TiGenix to discontinue cardiovascular pipeline

December 22, 2017 8:23 PM UTC

TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) said it will discontinue development of its allogeneic cardiovascular stem cell program, including AlloCSC-01, to focus on candidates derived from its expanded adipose-derived stem cell (eASC) platform, including Alofisel darvadstrocel (Cx601) and Cx611.

This month, CHMP backed approval of Alofisel to treat complex perianal fistulas in patients with Crohn’s disease (see BioCentury, Dec. 21). ...